Background and Purpose-Although recommended by guidelines, the benefits of treating patients with atrial fibrillation with a low-stroke risk score, with aspirin or anticoagulants, have not been clearly established. With advent of safer nonvitamin K antagonist oral anticoagulant, we assessed the clinical and economic implications of 5 mg BID of apixaban versus aspirin among patients with a relative low risk of stroke as assessed using the CHADS 2 (congestive heart failure, hypertension, age>75, diabetes mellitus, stroke/transient ischemic attack) and CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age, diabetes mellitus, stroke/transient ischemic attack, vascular disease) stroke risk classification.
A trial fibrillation (AF) is associated with a 4-to 5-fold increase in the risk of experiencing stroke. [1] [2] [3] Because of the mortality and morbidity associated with ischemic stroke, AF imposes a 1.5-fold increase in the cost of care, and the risk of death from AF-related stroke is doubled. 4, 5 Anticoagulation treatment is recommended to mitigate the risk of stroke in patients with AF, which for the past 5 decades had focused on treatment with vitamin K antagonists (VKAs; such as warfarin). 4, 5 Nonetheless, VKA therapy is limited by monitoring requirement, food-drug and drug-drug interactions, and bleeding effects, 6 resulting in research to assess the level of stroke risk in patients to provide recommendations for antithrombotic therapy. [7] [8] [9] [10] The CHADS 2 (congestive heart failure, hypertension, age>75, diabetes mellitus, stroke/transient ischemic attack) risk stratification algorithm, as recommended in numerous clinical guidelines, was used to estimate patients with stroke risk and treat them with VKA therapy. 5, 7, 11 The benefits of VKA therapy in patients with a CHADS 2 score of 1 were uncertain because of the balance in benefits versus the risks of treatment in terms of major bleeding. 5, 7, 11 An improved discriminative risk factor-based approach called the CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age, diabetes mellitus, stroke/transient ischemic attack, vascular disease) was introduced to better identify patients who could benefit from antithrombotic treatment. 4, 8 The CHA 2 DS 2 -VASc adds vascular disease, age 65 to 74 years, and sex category (female) to the CHADS 2 risk factors and has been shown to be superior to the CHADS 2 in identifying additional low-risk patients who However, despite refinements to the assessment of stroke risk and guideline recommendations to use anticoagulation, many patients with nonvalvular atrial fibrillation (NVAF) at lower spectrum of stroke risk get treated with aspirin, which may be suboptimal in terms of stroke prevention. 13, 14 These benefit risk evaluations for anticoagulation in lower-risk patients may be altered by the availability of non-VKA oral anticoagulants (NOACs). Clinical trials have shown them to be at least noninferior to VKAs in preventing strokes in patients with AF, with a better safety profile. [15] [16] [17] [18] Given that aspirin is a commonly used stroke prevention treatment in patients with AF at lower stroke risk, we wished to compare the risks and benefits of aspirin versus a NOAC in such patients. Apixaban is the only anticoagulant that has been compared with aspirin in a blinded randomized clinical trial, and it has superior efficacy and safety comparable with that of aspirin in patients with low risk of stroke and who are unsuitable for anticoagulation with VKA. 4, 19, 20 The net clinical benefit of expanding anticoagulation with NOACs versus aspirin in patients with low stroke risk is poorly understood. Therefore, the objective of this study was to assess the clinical and economic implications associated with NOAC implementation. As the Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial is the only randomized clinical trial that has explicitly compared aspirin with a NOAC (apixaban in this case), it was deemed as an ideal data set to assess the benefits and risks of extending treatment with apixaban versus aspirin to low-risk patients.
Methods

Design
A Markov cohort approach was used to determine the clinical and economic implications of using apixaban versus aspirin in patients with a CHADS 2 score of 1 and CHA 2 DS 2 -VASc score of 1 and in patients with a CHA 2 DS 2 -VASc score of 2 to 4. The latter 2 categories were derived from the AVERROES cohort by dividing patients with a CHADS 2 score 1 into 2 subgroups based on their CHA 2 DS 2 -VASc score. Associated healthcare costs, life years, and quality-adjusted life years (QALYs) for patients with NVAF in the United Kingdom (UK) were estimated over lifetime under each treatment regimen. Patients enter the model on the assigned treatment (ie, apixaban or aspirin). Depending on which treatment they are taking and population characteristic, patients are subjected to risks (ie, transition probabilities) of experiencing events as displayed in Figure 1 . The Markov model, including transition probabilities by each treatment, has been previously described in detail. 21, 22 
Event Rates
Secondary analysis was conducted on data from the AVERROES clinical trials to obtain event rates in patients with a CHADS 2 score of 1, and that group of patients was further subdivided into patients with CHA 2 DS 2 -VASc scores of 1 and 2 to 4 ( Table 1) . CHADS 2 was already collected in AVERROES; however, CHA 2 DS 2 -VASc was computed based on the CHADS 2 components and an additional vascular component. As the CHA 2 DS 2 -VASc was not collected in AVERROES, previous vascular disease (ie, part of the VASc component) was defined as peripheral artery disease as dictated by the case report forms (ie, other vascular disease components were not recorded).
Event rates for ischemic stroke and other major bleeds, per 100 patient-years, were derived for patients with a CHADS 2 score of 1 and CHA 2 DS 2 -VASc of scores of 1 and 2 to 4. Event rates for other events, including intracranial hemorrhage, myocardial infarction, systemic embolism (SE), clinically relevant nonmajor bleeds, cardiovascular hospitalizations, and treatment discontinuation, were derived for the subgroup of patients with a CHADS 2 score of 1 and assumed to be equal regardless of CHA 2 DS 2 -VASc score but varied by treatment, in accordance with previously published literature. 21 Rates for ischemic stroke (comprising ischemic and unspecified stroke), myocardial infarction, SE, and cardiovascular were based on the intention-to-treat population, whereas those for intracranial hemorrhage, clinically relevant nonmajor bleeds, other major bleeds, and other treatment discontinuation were based on the modified intention-to-treat population.
Cost and Utility Estimates
Utility estimates were obtained from a UK EuroQol 5 dimension (EQ-5D)-based catalog, 23 and published literature 24 as detailed in previous publications (Tables 2 and 3) . 21, 22 Costs were obtained from National Health Service reference costs, as previously published, 21, 22 and were updated to 2012 estimates 25 (Table 4) . Costs were estimated in 2012 British pounds and converted to US dollars at a rate of 1.48. Estimates of the healthcare costs associated with strokes were based on the Oxford Vascular Study, an updated population-based study. 26 The daily price of apixaban and aspirin was $3.26 and $0.03, respectively. 27 Cost and health outcomes were discounted at a rate of 3.5% per annum 28 over a lifetime horizon.
Deterministic Analyses
These analyses were taken from the perspective of the UK National Health Service, where only direct medical costs were considered. The analyses compared apixaban versus aspirin among subgroups of patients with CHA 2 DS 2 -VASc scores of 1 and 2 to 4, but also in patients with NVAF and CHADS 2 =1 in the UK allowing assessment of the incremental effect of updated guidelines versus traditional practice. Specifically, this analysis involved predicting the clinical outcomes over projected lifetime (assuming long-term mortality in a comparable population) 21, 22 for a cohort of 1000 patients with NVAF including the number of strokes avoided (including first and recurrent ischemic and hemorrhagic strokes), the number of major bleeds avoided (including first and recurrent hemorrhagic strokes, other intracranial hemorrhage, and other major bleeds), total costs over lifetime (including anticoagulant, monitoring, and event related costs), and total QALYs accrued over lifetime. Incremental cost-effectiveness ratio (ICER) was computed for each comparison to determine the lifetime costs/QALYs of apixaban versus aspirin.
The sensitivity of the base case results was evaluated by conducting probabilistic sensitivity analysis, where values of key input parameters are assigned a probability distribution and varied concurrently. This analysis was subjected to 2000 simulations by randomly drawing sets of inputs from their respective distributions and producing numbers of pairs of QALYs and costs. Results are presented in terms of scatter plots and cost-effectiveness acceptability curves. Table 5 shows the predicted number of clinical events that correspond to each treatment, for a cohort of 1000 patients with NVAF (VKA unsuitable) in the 3 subgroups of interest. Apixaban, in comparison with aspirin, was associated with 48, 87, and 34 fewer strokes or SEs over a lifetime horizon when used in patient populations with a CHADS 2 score of 1, CHA 2 DS 2 -VASc score of 1, and CHA 2 DS 2 -VASc score of 2 by guest on July 14, 2017 http://stroke.ahajournals.org/
Results
Base Case Analysis
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October 2015 to 4, respectively. However, treatment with apixaban when compared with aspirin was projected to have caused 24, 41, and 18 additional major bleeds in these 3 patient populations, respectively.
Patients tend to benefit through overall reduction in stroke and SE events despite the increase in the bleeding with net gains in QALYs of 0.185, 0.302, and 0.140 per patient treated with apixaban versus aspirin among the patient populations Figure 1 . Schematic representation model. M represents a Markov process with 11 health states that are identical for each of the 3 treatment options. All patients remain in the nonvalvular atrial fibrillation (NVAF) state until one of stroke, bleed, systemic embolism, myocardial infarction, treatment discontinuation, or death occurs. The transition probabilities of these events occurring depend on the treatment. For patients on second line aspirin (ie, the NVAF subsequent ASA health state), the events are identical; however, patients cannot experience any further discontinuation. Triangles indicate which health state the patient enters after an event. Health states colored in gray are permanent health states, with the remainder being transient health states occurring for a maximum period of 6 weeks before returning to the previous or subsequent health state. AC indicates anticoagulant; ASA, aspirin; CRNM, clinically relevant nonmajor; HS, hemorrhagic stroke; ICH, intracranial hemorrhage; and IS, ischemic stroke. *Intracranial hemorrhage event rate among patients unsuitable for VKA treatment was assumed to be the same in patients with CHA 2 DS 2 -VASc scores of 1 and 2-4 because of a small number of events observed in the apixaban and aspirin arms (2 and 1, respectively) . Per-patient costs increased despite a reduction in costs related to clinical event management, given the higher costs and longer duration of treatment with apixaban compared with aspirin, over a lifetime. In the subgroup of patients with a CHADS 2 score of 1, treatment with apixaban versus aspirin was associated with an additional cost of $4968 per patient over a lifetime. In the subgroups of patients with a CHA 2 DS 2 -VASc score of 1 and CHA 2 DS 2 -VASc score 2 to 4, the increase in per-patient costs over lifetime was $4225 and $5251 per patient, respectively.
Apixaban was deemed to be cost effective versus aspirin in across all subgroups of low-risk patients. The ICER per QALY gained was $26 852 in patients with a CHADS 2 score of 1, $14 001 in patients with a CHA 2 DS 2 -VASc score of 1, and $37 441 in patients with a CHA 2 DS 2 -VASc score of 2 to 4. These ratios are below the range of the commonly accepted threshold of $29 600 to $44 400 (ie, £20 000-£30 000) per QALY gained.
29
Probabilistic Sensitivity Analysis
For each of the low-risk subgroups, results of the probabilistic sensitivity analysis are plotted as the difference in the total aggregated costs between apixaban and aspirin on the y axis versus difference in QALYs accrued through lifetime use of these drugs on x axis (also known as cost-effectiveness plane; Figure 2 ). The cost-effectiveness planes illustrate the various cost and effect combinations of different strategies, as obtained by accounting for the uncertainty surrounding the base case inputs.
Apixaban was more effective, at incremental cost, with an ICER of <$44 400 (ie, £30 000) per QALY gained (ie, cost effective) in 70%, 88%, and 54% of simulations in the patients with a CHADS 2 score of 1, CHA 2 DS 2 -VASc score of 1, and CHA 2 DS 2 -VASc score of 2 to 4, respectively. The cost-effectiveness acceptability curves highlight that apixaban has a higher probability of being the most cost-effective treatment when compared with aspirin at willingness to pay thresholds of $31 080 per QALY gained and above when used in the subgroup of patients with a CHADS 2 score of 1. In patients with a CHA 2 DS 2 -VASc score of 1 and CHA 2 DS 2 -VASc score of 2 to 4, apixaban had the highest probability of being cost effective against aspirin at willingness to pay thresholds of $16 280 and $41 440 per QALY gained, respectively.
Discussion
Apixaban is associated with fewer strokes and SEs when compared with aspirin in patients with a CHADS 2 score of 1 who are unsuitable for VKA therapy, however, with additional major bleeding events. The ratio of the number of patients needed to treat to avoid an additional stroke over the number of patients needed to treat to harm with an additional bleed is estimated to be 0.5. Therefore, one additional major bleed is caused for every 2 strokes avoided. Over a lifetime horizon, the net reduction in clinical events results in increased QALY gains at marginal additional costs, deeming apixaban cost effective versus aspirin across all low-risk patients.
Previous analyses of the AVERROES trial have found no significant heterogeneity for treatment efficacy for apixaban versus aspirin when subdivided by stroke risk strata based on CHADS 2 /CHA 2 DS 2 -VASc, 30 therefore strengthening the validity of our findings. Our analysis expands on the findings from this study by assessing the effect of apixaban in low-risk patients over a lifetime. Our analysis varies in that only patients with a CHADS 2 score of 1 were considered (ie, patients with a CHA 2 DS 2 -VASc score of 1 or CHA 2 DS 2 -VASc score of 2-4 were only included if they had a CHADS 2 score of 1), and the outcomes analyzed were assessed to conform to the model definitions.
Our study is the first to focus on comparing the cost effectiveness of an NOAC versus aspirin among low-risk patients, thus allowing intensified management of stroke risk even in patients who are currently frequently treated with aspirin alone. Our analysis demonstrates that apixaban is cost effective versus aspirin across subgroups of low-risk patients and can offer substantial clinical benefits when administered according to either the CHA 2 DS 2 -VASc or CHADS 2 risk classification scheme. 4, 8 Therefore, this study supports intensified stroke prevention even in low-stroke risk patients as per international guidelines. 4, 20, 31 The model results suggest that the reduction in stroke and SE events is higher for apixaban when used in the lowest risk population of patients with a CHA 2 DS 2 -VASc score of 1 versus the patient population with a CHA 2 DS 2 -VASc score of 2 to 4 (ie, reduction of 84 strokes and SEs versus 34 strokes and SEs, respectively, among a cohort of 1000 patients). Although a priori expectations would suggest the opposite result, the reason for a larger numeric reduction in stroke events in the subgroup of patients with a CHA 2 DS 2 -VASc score of 1 is 2-fold: (1) lower all-cause mortality, leading to increased life expectancy and thereby increased absolute risk of stroke over a lifetime and, thus, greater absolute benefit from apixaban; and (2) numerically higher relative risk reduction (yet not significantly different) versus aspirin in stroke and SE. A similar and related finding was found in the additional number of major bleeding events observed, that is, a higher number *Number needed to treat to avoid one stroke and number needed to treat to harm with an additional bleed and their respective ratio can be referred to in text.
by guest on July 14, 2017 http://stroke.ahajournals.org/ Downloaded from of major bleeding events was observed among patients with a CHA 2 DS 2 -VASc score of 1, as well as a higher net (absolute over a lifetime) increase in bleeding events for apixaban when compared with patients with a CHA 2 DS 2 -VASc score of 2 to 4. This finding is mostly attributed to the observed rate of major bleeding in AVERROES being higher in the group of patients with a CHA 2 DS 2 -VASc score of 1 treated with apixaban, potentially because of longer exposure to apixaban.
The model used in this study followed the established structure of a previously published cost-effectiveness model, 21, 22 but it was expanded to include clinical data specific to patients at low risk of stroke and segregated by the CHA 2 DS 2 -VASc score of 1. Our findings are consistent with scenario analysis presented in the previous study, comparing apixaban with aspirin and warfarin in patients with a CHADS 2 score of ≤1. This scenario found that apixaban was cost effective to aspirin and warfarin in patients with a CHADS 2 score of ≤1 at ICERs of £16 744 and £13 152 (ie, $24 781 and $19 465), respectively. 21 As with all models, several limitations apply to our analysis. The use of clinical trial data to inform event rates may not reflect actual clinical practice rates in the UK population. However, real-world studies suggest that clinical trial results for NOACs are broadly comparable with real-world data. 32 Similarly, as the CHA 2 DS 2 -VASc was not collected in AVERROES, 19 this was computed from baseline characteristics in retrospect. The vascular component of the CHA 2 DS 2 -VASc included peripheral artery disease, but other aspects, such as previous myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft, were not recorded. This was similar to the approach followed in a previous analysis of AVERROES. 30 This limitation could suggest that a few patients classified in the subgroup of patients with a CHA 2 DS 2 -VASc score of 1 should have been classified in the subgroup of patients with a CHA 2 DS 2 -VASc score of 2 to 4 because a higher risk of stroke. However, the obtained stroke and major bleeding risks followed the expected direction (ie, higher risks 
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in the subgroup of patients with a CHA 2 DS 2 -VASc score of 2-4) and were within the range reported in the published literature. [33] [34] [35] [36] For example, the estimated annual ischemic stroke risk for aspirin-treated patients with a CHA 2 DS 2 -VASc score of 1 used in this study was 1.37%, comparable, and in most cases, lower than estimates from nationwide cohort studies in untreated patients. [33] [34] [35] [36] Given the range presented in the literature, it is unclear as to whether adjustment for this limitation could have led to any incremental changes in results and whether this would improve or worsen health gains for apixaban in either of the 2 CHA 2 DS 2 -VASc subgroups. Despite this uncertainty, aggregate results in the overall CHADS 2 =1 group of patients suggest that apixaban is a cost-effective alternative to aspirin at an ICER of $26 852 per QALY gained, which is below the lowest adopted threshold. Given the bias is present across both treatment groups and in light of cost-effectiveness results in the overall low-risk population and estimates from the published literature, it is unlikely that this limitation would alter the conclusions of the analysis. In addition, results from the probabilistic analysis suggest that the conclusions of the analysis are robust to uncertainty surrounding the parameter inputs.
It is important to note that this study does not directly compare CHA 2 DS 2 -VASc and CHADS 2 risk scores but rather emphasizes the importance of intensified anticoagulation in all (guideline indicated) low-risk patients. In the future, it will be important to gain a further understanding of the relative contribution of various risk factors including age, sex, and other comorbidities that comprise of the lower CHA 2 DS 2 -VASc scores and to assess the clinical and economic implications of anticoagulation according to various patient profiles with the same CHA 2 DS 2 -VASc score. For example, the study by Coppens et al 37 suggests that age may be a more important factor versus other risk factors.
In conclusion, anticoagulant treatment with apixaban versus aspirin in low-risk patients, as identified using CHADS 2 or CHA 2 DS 2 -VASc, is projected to increase life expectancy and provide acceptable clinical benefits in terms of expected number of strokes avoided versus bleeds. These benefits are accrued at an additional cost but were deemed cost effective. Our findings reinforce recommendations that patients with a CHA 2 DS 2 -VASc score of ≥1 should be treated with anticoagulation from both the clinical and economic standpoint.
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